Navigation Links
Molecular link between diabetes and cancer described
Date:11/15/2011

Developing type 2 diabetes is a lengthy process. An early sign that it has begun is high levels of insulin in the blood. As long as the insulin-producing beta cells are able to compensate for the increased demand, for example when the individual is overweight, the blood sugar levels remain normal. It is not until the capacity for insulin secretion falls below the level needed that type 2 diabetes becomes a fact. The latter stage generally goes quickly, as the stressed beta cells work themselves to death.

"We have worked with the most well-known risk gene for type 2 diabetes, a variant of the TCF gene, and have studied its function in the beta cells", says Yuedan Zhou, a doctoral student at the Lund University Diabetes Centre and principal author of the published study.

The risk variant of TCF is common, 25 per cent of the population carry it and 31 per cent of diabetics, according to figures from the Malm Preventive Project population survey.

An equally well-established risk gene in cancer research is p53. The gene has been called the "protector of the genome" because it prevents the uncontrolled cell division that takes place in cancer. The p53 gene has been linked to protection against colon and liver cancer, among others.

"The function of the TCF gene in the beta cells is to protect the cells against high, stressful blood sugar levels. If that function fails, the beta cells die, which leads to diabetes", says Ola Hansson, researcher and principal author of the survey.

The two genes work in concert, TCF protects against cell death, while p53 prevents excessive cell division.

"It is here that the connection between diabetes and cancer arises. When the blood sugar levels are high, the TCF gene is activated and this impedes the activity of the p53 gene thereby protecting the beta cells from cell death" .

The research group began working with the TCF gene two years ago to understand its role in insulin production. The discovery of the link with p53 and cancer was mostly by chance.

"Or good intuition", they say.

The mapping of the TCF gene is continuing, this time in collaboration with the European Bioinformatics Institute in Cambridge.

Cancer researchers are working to try and influence p53 so that its tumour-preventing function is restored.

"In a similar way, strengthening the protective function of TCF against beta cell death in connection with high blood sugar would work as a drug for type 2 diabetes, or as a treatment before the disease has even developed fully", says Ola Hansson.


'/>"/>

Contact: Ola Hansson
Ola.Hansson@med.lu.se
46-739-549-923
Lund University
Source:Eurekalert

Related medicine news :

1. AACR-NCI-EORTC to hold molecular targets meeting in San Francisco
2. Nobel Laureate Bruce Beutler on molecular sensors as a trigger for autoimmune disease
3. Biodesign researchers to develop new reagent pipeline for molecular medicine
4. Molecular depth profiling modeled using buckyballs and low-energy argon
5. New equation predicts molecular forces in hydrophobic interactions
6. AACR hosts molecular targets and cancer therapeutics conference
7. Researchers identify potential molecular target to prevent growth of cancer cells
8. New clues to molecular understanding of autism
9. Molecular meet and greet
10. Hebrew U. scientists identify molecular basis for DNA breakage
11. Blocking molecular target could make more cancers treatable with PARP inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, ... announced today that a new solution for Emergency Departments (ED) has been added ... space in Emergency Department examination rooms, and with a simplified pallet of information ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... Plainsboro, NJ (PRWEB) , ... December 08, 2016 , ... ... patients, cancer centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts ... In making the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching of ... Unified Instance Manager architecture, meeting the needs of multichannel growth and doubling ... unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets ... 2016-2020" report to their offering. ... The report forecasts the global optical transceiver ... 2016-2020. The report covers the present scenario and ... To calculate the market size, the report considers the revenue generated ...
(Date:12/9/2016)... Dec. 9, 2016  Harmar Mobility, LLC announced today that Steven ... of the Board of Directors. Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... ... Mr. Dawson,s executive career includes ... across a variety of industries. He brings to the company deep ...
(Date:12/9/2016)... Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... of Physiocrine-based therapeutics to address severe, rare diseases, today announced that ... BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel ... 14, 2016, at 4:20 p.m. ET. About aTyr ... aTyr ...
Breaking Medicine Technology: